Methodology Devised to Improve Stem Cell Reprogramming
|
By LabMedica International staff writers Posted on 27 Jan 2015 |

Image: Induced pluripotent stem (iPS) cells, which act very much like embryonic stem cells, are shown growing into heart cells (blue) and nerve cells (green) (Photo courtesy of Gladstone Institutes/Chris Goodfellow).

Image: Microscopic view of a colony of induced pluripotent stem cells obtained by reprogramming a specialized cell for two weeks (Photo courtesy of UCLA Broad Stem Cell Research Center/Plath Lab).
In a study that provides scientists with a critical new determination of stem cell development and its role in disease, researchers have established a first-of-its-kind approach that outlines the stages by which specialized cells are reprogrammed into stem cells resembling those found in embryos. The research could have wide ranging, long-term implications in enhancing disease modeling and devising new therapies for patients.
The study, conducted by researchers from the University of California, Los Angeles (UCLA; USA) Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and led by Dr. Kathrin Plath, a professor of biological chemistry, was published January 2015 in the journal Cell. Induced pluripotent stem cells (iPSCs) are cells that can be generated from adult cells and then, like embryonic stem cells, be directed to become any cell in the human body. Adult cells can also be reprogrammed in the lab to change from a specialized cell back to an iPSC (and thereby becoming a cell similar to that of an embryonic stem cell).
Reprogramming takes one to two weeks and is a mostly inefficient process, with typically less than one percent of the beginning cells effectively becoming an iPSC. The exact stages a cell goes through during the reprogramming process are not well understood. This knowledge is vital, because iPSCs have great potential in the field of regenerative medicine, as they can constantly reproduce and provide a single source of patient-specific cells to replace those lost to injury or disease. They can also be used to create innovative disease models from which new drugs and therapies can be developed.
Vincent Pasque and Jason Tchieu, postdoctoral fellows in Plath’s lab and co-first authors of the study, developed a roadmap of the reprogramming process using detailed time-course analyses. They induced the reprogramming of specialized cells (that could only make more of themselves, and no other cell types), then observed and analyzed on a daily basis or every other day the process of transformation at the single-cell level. The data were gathered and recorded during a time period of up to two weeks.
Dr. Plath’s team found that the changes that happen in cells during reprogramming occur in sequentially, and that notably, the stages of the sequence were the same across the diverse reprogramming systems and different cell types analyzed. “The exact stage of reprogramming of any cell can now be determined,” Dr. Pasque said. “This study signals a big change in thinking, because it provides simple and efficient tools for scientists to study stem cell creation in a stage-by-stage manner. Most studies to date ignore the stages of reprogramming, but we can now seek to better understand the entire process on both a macro and micro level.”
Dr. Plath’s group additionally discovered that the stages of reprogramming to iPSC are different from what was expected. They found that it is not simply the reversed sequence of stages of embryo development. Some steps are reversed in the expected order; others do not actually happen in the exact reverse order and resist a change until late during reprogramming to iPSCs. “This reflects how cells do not like to change from one specialized cell type to another and resist a change in cell identity,” Dr. Pasque said. “Resistance to reprogramming also helps to explain why reprogramming takes place only in a very small proportion of the starting cells.”
With these findings, Dr. Plath’s lab plans future studies to actively isolate specific cell types during specific stages of reprogramming. They also hope the research will encourage further investigation into the characteristics of iPSC development. “This research has broad impact, because by understanding cell reprogramming better we have the potential to improve disease modeling and the generation of better sources of patient-specific specialized cells suitable for replacement therapy,” concluded Dr. Plath. “This can ultimately benefit patients with new and better treatments for a wide range of diseases.”
Related Links:
University of California, Los Angeles’ Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
The study, conducted by researchers from the University of California, Los Angeles (UCLA; USA) Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and led by Dr. Kathrin Plath, a professor of biological chemistry, was published January 2015 in the journal Cell. Induced pluripotent stem cells (iPSCs) are cells that can be generated from adult cells and then, like embryonic stem cells, be directed to become any cell in the human body. Adult cells can also be reprogrammed in the lab to change from a specialized cell back to an iPSC (and thereby becoming a cell similar to that of an embryonic stem cell).
Reprogramming takes one to two weeks and is a mostly inefficient process, with typically less than one percent of the beginning cells effectively becoming an iPSC. The exact stages a cell goes through during the reprogramming process are not well understood. This knowledge is vital, because iPSCs have great potential in the field of regenerative medicine, as they can constantly reproduce and provide a single source of patient-specific cells to replace those lost to injury or disease. They can also be used to create innovative disease models from which new drugs and therapies can be developed.
Vincent Pasque and Jason Tchieu, postdoctoral fellows in Plath’s lab and co-first authors of the study, developed a roadmap of the reprogramming process using detailed time-course analyses. They induced the reprogramming of specialized cells (that could only make more of themselves, and no other cell types), then observed and analyzed on a daily basis or every other day the process of transformation at the single-cell level. The data were gathered and recorded during a time period of up to two weeks.
Dr. Plath’s team found that the changes that happen in cells during reprogramming occur in sequentially, and that notably, the stages of the sequence were the same across the diverse reprogramming systems and different cell types analyzed. “The exact stage of reprogramming of any cell can now be determined,” Dr. Pasque said. “This study signals a big change in thinking, because it provides simple and efficient tools for scientists to study stem cell creation in a stage-by-stage manner. Most studies to date ignore the stages of reprogramming, but we can now seek to better understand the entire process on both a macro and micro level.”
Dr. Plath’s group additionally discovered that the stages of reprogramming to iPSC are different from what was expected. They found that it is not simply the reversed sequence of stages of embryo development. Some steps are reversed in the expected order; others do not actually happen in the exact reverse order and resist a change until late during reprogramming to iPSCs. “This reflects how cells do not like to change from one specialized cell type to another and resist a change in cell identity,” Dr. Pasque said. “Resistance to reprogramming also helps to explain why reprogramming takes place only in a very small proportion of the starting cells.”
With these findings, Dr. Plath’s lab plans future studies to actively isolate specific cell types during specific stages of reprogramming. They also hope the research will encourage further investigation into the characteristics of iPSC development. “This research has broad impact, because by understanding cell reprogramming better we have the potential to improve disease modeling and the generation of better sources of patient-specific specialized cells suitable for replacement therapy,” concluded Dr. Plath. “This can ultimately benefit patients with new and better treatments for a wide range of diseases.”
Related Links:
University of California, Los Angeles’ Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
Latest BioResearch News
- BRCA2 Variant Analysis Offers Insights Into Breast Cancer Risk and Treatment
- Statistical Model Helps Track T Cell Behavior During Cancer Immunotherapy
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







